Herman Eisen passed away on November 2, 2014, at the age of 96. During his long and distinguished career, Herman was a mentor to those who trained in his laboratory (ourselves included), to those who collaborated with him over the years, and to many faculty and colleagues at Massachusetts Institute of Technology (MIT) and elsewhere. He will be missed by all.
Herman's long-standing and classic work with antibodies was remarkable, having yielded many honors, including election to the American Academy of Arts and Sciences, the National Academy of Sciences, and the Institute of Medicine, along with the Behring-Heidelberger and Lifetime Achievement Awards, both from the American Association of Immunologists (AAI Herman was a legend in the field of immunology, and his work spanned a wide range of topics, all tied together by the theme of antigen recognition and specificity. He began a long line of impressive discoveries by establishing definitively, in a seminal 1949 paper with his friend Fred Karush, that antibodies were bivalent (5). Later, Herman was the first to show that antibodies increase in affinity over time (6) (called affinity maturation), a process that is now used in the development of virtually every antibody-based drug. In a series of studies done before monoclonal antibodies were available (i.e., from hybridomas), he showed that myeloma proteins could be used to understand antigen binding in a homogeneous, tractable system (7).
However, his interest in antibodies was only the start. After four decades of work in the antibody field, he started a second career in the field of T cells. His move into this area may have been spurred by his earlier experiments, some of which he performed on himself (1, 2), showing that skin hypersensitivity to small inorganic molecules was mediated by T cells. The myeloma tumors that he had studied in the 1960s also served a purpose in his first foray into T cells in the 1970s. In this work, Herman's laboratory examined the ability of cytotoxic T lymphocytes (CTLs) to recognize and eliminate myeloma cells (8) , for which the myeloma protein could serve as an antigen.
In the early 1980s, Herman decided to devote more effort toward understanding antigen recognition by T cells. His group at the time (Fig. 1) was about equally divided between antibody and T-cell projects. Most individuals who were entering the laboratory tried their hand at cloning mouse CTL lines to investigate various aspects of the specificity mediated by the then undefined antigen receptor (or receptors). One of us (D.M.K.) was charged with trying to identify the T-cell receptor by producing monoclonal antibodies to cell surface molecules. Soon this led to a productive collaborative effort with Susumu Tonegawa, and the genes encoding the gamma and alpha chains of T-cell receptors were identified, albeit in a rather circuitous fashion (1).
Perhaps less recognized is the fact that, in the mid-1980s, Herman's laboratory was working on bispecific antibodies (he called them heteroantibody duplexes) (9), long before the more recent flurry of activity. He was also among the first to describe some of the components of the CTL killing machinery: the serine esterases. A look at his papers through those years illustrates how Herman was involved in many of the early discoveries that have now become textbook material in the recognition and function of T cells. The parallel with his "first career" in the antibody field is striking. In fact, one of us (D.M.K.) once remarked that he seemed like a real-life case of Benjamin Button.
After his initial decade of T-cell work, Herman returned to his roots with regard to the understanding of antigen recognition. Coming full circle, in the 1990s, Herman's laboratory (Fig. 1) identified naturally occurring antigens (peptides) recognized by T cells (10, 11) , and they measured the affinity and kinetics of the T-cell antigen receptor for its ligands (12) . His deep understanding of the chemical basis of recognition continued to shape his thinking about the specificity of these two types of lymphocyte receptors: antibodies and T-cell receptors.
We, like others in the laboratory, enjoyed immensely the environment that Herman fostered in his relatively modest-sized laboratory. Group meetings were Thursday mornings, and Herman invariably brought coffee cake or cookies from a local bakery. We also had an annual cookout at his place in Woods Hole, MA, where Herman loved to spend time relaxing with his wife Natalie and tending to his garden.
Herman published papers every year since 1946, spanning eight decades. Writing a paper with Herman was itself a valuable lesson (if not at times frustrating for his postdocs, as a paper could take a year to complete). Early drafts rarely resembled final manuscripts, and he carefully studied every word and phrase. He could frame a problem in terms that were clear, concise, and important. There was little hype, lots of quantitation, and ample use of qualifiers to aspects that were not definitive. He was to our minds the perfect scientist.
In the last decade or so, Herman was able to maintain his science "fix" by working with colleagues on their projects. These included a fruitful series of studies with Jianzhu Chen (MIT), many intellectually satisfying interactions with Arup Chakraborty (MIT), and the occasional projects he worked on with both of us.
A scholar until the end, Herman spent the morning that he passed away working on a manuscript. Apropos of where it all started, the paper considers why antibody affinities remain quite heterogeneous rather than evolving toward only high-affinity species. This is how we will remember him, always enjoying the intellectual stimulation that comes with unanswered questions in science.
